Long-term Risk of Prostate Cancer Mortality Among Men with Baseline Prostate-specific Antigen Below 3 ng/ml: Evidence from the Finnish Randomized Study of Screening for Prostate Cancer
In this study, we analyzed prostate cancer deaths in Finnish men with low initial prostate-specific antigen (PSA) levels. We found that the risk of prostate cancer death increases in relation to PSA, especially in younger men. Screening might safely be stopped at ages 67-71 yr if PSA remains low.
Authors
- Teuvo L.J. Tammela (ORCID: https://orcid.org/0000-0002-3529-4649)
- Kirsi Talala (ORCID: https://orcid.org/0000-0002-9705-9265)
- Jani Raitanen (ORCID: https://orcid.org/0000-0001-7674-0978)
- Anssi Auvinen (ORCID: https://orcid.org/0000-0003-1125-4818)
- Idris Ola (ORCID: https://orcid.org/0000-0002-0133-0103)
- Kimmo Taari (ORCID: https://orcid.org/0000-0002-0077-4896)
- Teemu J. Murtola (ORCID: https://orcid.org/0000-0003-2932-9590)
- Paula Kujala
Institutions
- University of Helsinki (FI)
- Tampere University of Applied Sciences (FI)
- Heidelberg University (DE)
- Helsinki University Hospital (FI)
- University Hospital Heidelberg (DE)
- Tampere University Hospital (FI)
- Tampere University (FI)
- Fimlab (Finland) (FI)
- Cancer Society of Finland (FI)
- Urho Kaleva Kekkonen Institute (FI)
Publication Details
- Journal
- European Urology Oncology
- Published
- 2024-12-06
- DOI
- https://doi.org/10.1016/j.euo.2024.11.010
- Citations
- 4
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 1.68